Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats.
about
Human conditions of insulin-like growth factor-I (IGF-I) deficiencyGH and the cardiovascular system: an update on a topic at heartInsulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism.Repopulation of the atrophied thymus in diabetic rats by insulin-like growth factor I.Insulin-like growth factor I stimulates erythropoiesis in hypophysectomized ratsEffects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects.Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats.Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humansInsulin-like growth factor 1 (IGF-1): a growth hormoneEffect of GH/IGF-1 on Bone Metabolism and Osteoporsosis.Differential effects of insulin-like growth factor I and growth hormone on developmental stages of rat growth plate chondrocytes in vivo.Insulin-like growth factor-1 stimulation of lymphopoiesisIntravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats.Adaptation of the growth hormone and insulin-like growth factor-I axis to chronic and severe calorie or protein malnutrition.Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated ratsRegulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia.Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5.Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytesLiver-derived IGF-I contributes to GH-dependent increases in lean mass and bone mineral density in mice with comparable levels of circulating GH.The therapeutic potential of recombinant human insulin-like growth factor-I.Disproportionate growth in mice with Igf-2 transgenesGenetic regulation of the growth plateLow Insulin-Like Growth Factor-1 Level in Obesity Nephropathy: A New Risk Factor?A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axisApplication of autologous derived-platelet rich plasma gel in the treatment of chronic wound ulcer: diabetic foot ulcer.Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene productLiver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in miceGrowth hormone, insulin-like growth factors, and the skeleton.Growth hormone induces multiplication of the slowly cycling germinal cells of the rat tibial growth plateInsulin-like growth factor I accelerates recovery from ischemic acute tubular necrosis in the rat.Engineering insulin-like growth factor-1 for local delivery.The role of liver-derived insulin-like growth factor-I.Age-related alterations of the growth hormone/insulin-like-growth-factor I axis.Insulin-like growth factor-1 is a potent neuronal rescue agent after hypoxic-ischemic injury in fetal lambsThe effects of infusion of insulinlike growth factor (IGF) I, IGF-II, and insulin on glucose and protein metabolism in fasted lambs.The insulin-like growth factor-I/binding protein axis: physiology, pathophysiology and therapeutic manipulation.Role of IGF system of mitogens in the induction of fibroblast proliferation by keloid-derived keratinocytes in vitro.Unanswered questions concerning the treatment of hyposomatotropism and hypogonadism in elderly men.
P2860
Q26822806-DEEFAAA2-A1B4-4744-ABF5-B48CE3AAC16EQ27002329-ABC7B026-879B-4F80-86B5-9AEFC4127114Q30466219-81C6B4B9-6125-413D-AEE4-683EB293DBE5Q33579200-30921BD4-12DF-4105-A264-450DAB5E653BQ33658083-823ADCBA-9C14-4930-8B16-6AC7449DC7B8Q33851134-8A37603E-C533-4D66-8B91-020858D60ED5Q33858784-525B82F3-A3BB-461D-8ACF-46DDA4C43122Q33888618-24DB74C4-8CC9-4C1E-A2C6-89A312F6627FQ33907536-122AE3E9-9A24-49E3-879D-95B29D79BEB8Q33918809-7D47F18E-84F7-4D46-BEBF-9F5FB0F11F2DQ34043294-A7EF1ACC-098B-474B-8E4B-C7442FDFE0B1Q34131991-C0901214-AFAA-48A5-8EF2-5AC39B60B815Q34169714-8A0E84FE-ECDB-49F0-9120-6E13B2F5FE74Q34194165-7B2B2C1E-4278-4735-A1DB-9766A54ABB7FQ34218414-9157D1EB-DDB9-4430-944A-B4FDD3F42DA6Q34248120-9C957B75-B6B3-46D5-AD22-1ADB74FCF7DEQ34260846-17E3486A-6E27-4F2B-B898-7AD9FC2D1B31Q34457990-7B08309E-197C-491F-87B6-F23577656FD7Q34572977-1B12BF88-BD1A-4983-A50F-93D580F7D2F4Q35067296-754A779D-C25A-4EB0-A709-48A0A4EFB3F3Q35073629-2CAC6825-FEA3-42CE-8AAF-AC9AEFE3E391Q35479134-6153B868-ABA0-4E92-BF55-3B518EC580CBQ35850859-264E3A54-2357-4B49-99A7-96B4C5B92976Q35972282-A5778B22-8472-4749-A1D4-C7F4CA829768Q36006630-C5E99DB0-A3CF-41ED-A369-4B7D4D9FAAEBQ36190743-EE1B34D0-2AF8-4671-B548-914A0F5E031BQ36374514-5695986B-3540-42E3-8CF7-F02435CC0722Q36378010-49F40B11-8ACD-4C80-9EF1-30F480E6D5CCQ36392687-C18CBD2D-2654-4B12-B6FD-7ADA4D1D7141Q37147591-CF71D0D5-4B0F-4E0F-9744-BA4F1006C781Q37255272-618829D0-5327-492D-B05D-B03B220FF087Q37342579-53EB4BC5-C923-4952-9B81-222686567811Q37368900-9AC7C47B-2619-4512-9B72-AF6B30EDFFAFQ37381848-4816BE7E-2AAF-43A4-9BC0-8C1F55691DE7Q37669488-ABBB853F-B3CC-418B-AB36-92C10954C14BQ39757754-0E55AC05-5DCE-4DC2-8F87-EC7A37CCA171Q40341473-5B8307B6-62E9-4859-BAF4-8CA494E6BBF8Q40492402-54E3EC5E-264B-49CA-81F8-EB7D25C8CE54Q40666079-5F58599C-3D45-4443-8E10-84BFDF12EAA7Q40749572-BD64776D-3D85-4F34-8FCE-F6E545A6FE7E
P2860
Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats.
description
1988 nî lūn-bûn
@nan
1988 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Recombinant human insulin-like ...... ize in hypophysectomized rats.
@ast
Recombinant human insulin-like ...... ize in hypophysectomized rats.
@en
Recombinant human insulin-like ...... ize in hypophysectomized rats.
@nl
type
label
Recombinant human insulin-like ...... ize in hypophysectomized rats.
@ast
Recombinant human insulin-like ...... ize in hypophysectomized rats.
@en
Recombinant human insulin-like ...... ize in hypophysectomized rats.
@nl
prefLabel
Recombinant human insulin-like ...... ize in hypophysectomized rats.
@ast
Recombinant human insulin-like ...... ize in hypophysectomized rats.
@en
Recombinant human insulin-like ...... ize in hypophysectomized rats.
@nl
P2093
P2860
P356
P1476
Recombinant human insulin-like ...... ize in hypophysectomized rats.
@en
P2093
P2860
P304
P356
10.1073/PNAS.85.13.4889
P407
P577
1988-07-01T00:00:00Z